Share Price and Basic Stock Data
Last Updated: November 20, 2025, 8:23 pm
| PEG Ratio | 1.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
RPG Life Sciences Ltd operates in the pharmaceuticals sector, with its share price currently at ₹2,225 and a market capitalization of ₹3,675 Cr. The company has reported a consistent upward trajectory in its revenue, with sales for the fiscal year ending March 2025 standing at ₹653 Cr, up from ₹513 Cr in March 2023. This translates to a compound annual growth rate (CAGR) of approximately 13.68% over two years. Notably, the latest quarterly report for June 2025 recorded sales of ₹169 Cr, reflecting a strong demand trend. The operating profit margin (OPM) has also improved, increasing from 20% in March 2023 to 25% in March 2025, indicating better cost control and operational efficiency. The company has reported a steady increase in sales across the quarters, with ₹154 Cr in September 2023 and a projected ₹173 Cr in December 2024, showcasing its ability to adapt to market conditions and consumer needs.
Profitability and Efficiency Metrics
RPG Life Sciences has demonstrated robust profitability metrics, with a net profit of ₹183 Cr reported for the fiscal year ending March 2025, up from ₹68 Cr in the previous year. This surge in profit is accompanied by a significant increase in earnings per share (EPS), which rose to ₹110.80, compared to ₹40.90 in March 2023. The return on equity (ROE) for the company stood at an impressive 34.53%, indicating effective management of shareholder funds. The interest coverage ratio (ICR) is extraordinarily high at 277.95x, reflecting the absence of debt, which enhances financial stability. Additionally, the net profit margin improved to 28.04%, showcasing effective cost management and operational efficiency. The company’s operating profit margin also indicates a healthy level of profitability, rising to 25% in March 2025 from 20% in March 2023, thereby positioning RPG Life Sciences favorably against industry standards.
Balance Sheet Strength and Financial Ratios
The balance sheet of RPG Life Sciences is notably strong, with total assets reported at ₹658 Cr as of March 2025, a substantial increase from ₹419 Cr in March 2023. The company maintains a zero-debt position, with borrowings recorded at ₹0 Cr, which significantly enhances its financial health and flexibility. Reserves have increased to ₹541 Cr, reflecting the company’s capacity to reinvest in growth initiatives. The current ratio stands at 3.88, indicating strong liquidity and the ability to cover short-term liabilities comfortably. The price-to-book value (P/BV) ratio is currently at 7.10x, which may suggest that the stock is trading at a premium compared to its book value, a common characteristic in high-growth sectors. Furthermore, the return on capital employed (ROCE) stood at 33%, underlining efficient utilization of capital for generating profits.
Shareholding Pattern and Investor Confidence
The shareholding pattern of RPG Life Sciences reveals a stable structure, with promoters holding 72.95% of the equity as of March 2025. This significant promoter stake is a positive indicator of management’s commitment to the company’s long-term growth. Foreign institutional investors (FIIs) have gradually increased their stake to 1.11%, while domestic institutional investors (DIIs) hold 6.70%, both reflecting growing investor confidence. The total number of shareholders has also risen to 26,657, indicating increased retail participation. However, the public shareholding has decreased from 27.11% in December 2022 to 19.23% in March 2025, which may raise concerns about liquidity and market sentiment. The high promoter holding, combined with increasing institutional participation, signals strong confidence in the company’s strategic direction and future performance.
Outlook, Risks, and Final Insight
Looking ahead, RPG Life Sciences is well-positioned for continued growth, supported by strong financials and operational efficiency. The company’s focus on expanding its product portfolio and increasing market share may drive further revenue growth. However, potential risks include regulatory challenges in the pharmaceutical industry and competition from both domestic and international players. Additionally, the dependency on a few key products could pose risks to revenue stability. If the company successfully navigates these challenges, it could enhance its market position and profitability. Conversely, failure to address these risks may impact growth. Overall, RPG Life Sciences presents a compelling investment opportunity, contingent on its ability to sustain growth and manage inherent industry risks effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of RPG Life Sciences Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 159 Cr. | 127 | 247/84.3 | 35.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,612 Cr. | 423 | 479/192 | 95.5 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.0 Cr. | 43.1 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.2 Cr. | 26.1 | 29.1/17.0 | 91.1 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,228.23 Cr | 1,183.75 | 53.16 | 202.47 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 129 | 135 | 131 | 118 | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 |
| Expenses | 101 | 105 | 101 | 103 | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 |
| Operating Profit | 28 | 30 | 29 | 16 | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 |
| OPM % | 22% | 22% | 22% | 13% | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% |
| Other Income | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 25 | 27 | 26 | 14 | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 |
| Tax % | 28% | 26% | 26% | 25% | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% |
| Net Profit | 18 | 20 | 19 | 10 | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 |
| EPS in Rs | 11.01 | 12.07 | 11.55 | 6.26 | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 |
Last Updated: August 1, 2025, 1:05 pm
Below is a detailed analysis of the quarterly data for RPG Life Sciences Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 169.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 169.00 Cr., marking an increase of 26.00 Cr..
- For Expenses, as of Jun 2025, the value is 133.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 118.00 Cr. (Mar 2025) to 133.00 Cr., marking an increase of 15.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 35.00 Cr.. The value appears strong and on an upward trend. It has increased from 25.00 Cr. (Mar 2025) to 35.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Jun 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 21.00%, marking an increase of 3.00%.
- For Other Income, as of Jun 2025, the value is 5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 115.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 110.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 135.00 Cr. (Mar 2025) to 35.00 Cr., marking a decrease of 100.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 13.00% (Mar 2025) to 26.00%, marking an increase of 13.00%.
- For Net Profit, as of Jun 2025, the value is 26.00 Cr.. The value appears to be declining and may need further review. It has decreased from 117.00 Cr. (Mar 2025) to 26.00 Cr., marking a decrease of 91.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 15.90. The value appears to be declining and may need further review. It has decreased from 70.95 (Mar 2025) to 15.90, marking a decrease of 55.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:33 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 513 | 582 | 653 | 666 |
| Expenses | 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 408 | 453 | 493 | 517 |
| Operating Profit | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 104 | 129 | 161 | 149 |
| OPM % | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% | 22% | 25% | 22% |
| Other Income | 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | 7 | 95 | 139 |
| Interest | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 16 | 17 | 21 | 21 |
| Profit before tax | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 92 | 118 | 233 | 267 |
| Tax % | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | 26% | 26% | 21% | |
| Net Profit | 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 68 | 88 | 183 | 215 |
| EPS in Rs | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 40.90 | 53.00 | 110.79 | 130.25 |
| Dividend Payout % | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% | 29% | 30% | 22% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -98.11% | 1100.00% | 75.00% | -38.10% | -15.38% | 163.64% | 37.93% | 27.50% | 33.33% | 29.41% | 107.95% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1198.11% | -1025.00% | -113.10% | 22.71% | 179.02% | -125.71% | -10.43% | 5.83% | -3.92% | 78.54% |
RPG Life Sciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 14% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 63% |
| 5 Years: | 29% |
| 3 Years: | 31% |
| TTM: | 12% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 46% |
| 3 Years: | 46% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 24% |
| 3 Years: | 25% |
| Last Year: | 26% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: November 9, 2025, 2:50 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 294 | 362 | 517 | 541 |
| Borrowings | 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | 0 | 0 | 0 |
| Other Liabilities | 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 112 | 138 | 127 | 152 |
| Total Liabilities | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
| Fixed Assets | 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 124 | 114 | 172 | 179 |
| CWIP | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 25 | 96 | 16 | 27 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 91 | 127 | 93 |
| Other Assets | 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 211 | 212 | 343 | 407 |
| Total Assets | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 419 | 513 | 658 | 706 |
Below is a detailed analysis of the balance sheet data for RPG Life Sciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 541.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 541.00 Cr., marking an increase of 24.00 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 152.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 127.00 Cr. (Mar 2025) to 152.00 Cr., marking an increase of 25.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 706.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 658.00 Cr. (Mar 2025) to 706.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 179.00 Cr.. The value appears strong and on an upward trend. It has increased from 172.00 Cr. (Mar 2025) to 179.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 27.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 27.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 127.00 Cr. (Mar 2025) to 93.00 Cr., marking a decrease of 34.00 Cr..
- For Other Assets, as of Sep 2025, the value is 407.00 Cr.. The value appears strong and on an upward trend. It has increased from 343.00 Cr. (Mar 2025) to 407.00 Cr., marking an increase of 64.00 Cr..
- For Total Assets, as of Sep 2025, the value is 706.00 Cr.. The value appears strong and on an upward trend. It has increased from 658.00 Cr. (Mar 2025) to 706.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (541.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -3.00 | -19.00 | 0.00 | -25.00 | -16.00 | -2.00 | 48.00 | 69.00 | 86.00 | 104.00 | 129.00 | 161.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 | 27 | 31 | 48 |
| Inventory Days | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 | 203 | 200 | 159 |
| Days Payable | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 | 138 | 140 | 135 |
| Cash Conversion Cycle | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 | 91 | 90 | 72 |
| Working Capital Days | 30 | 27 | 26 | 20 | 22 | 20 | 41 | 52 | 47 | 33 | 25 | 45 |
| ROCE % | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% | 33% | 35% | 33% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Mirae Asset Multicap Fund | 165,269 | 1.18 | 22.98 | 165,269 | 2025-04-22 16:51:54 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 47 | 0.07 | 0.01 | 47 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 |
| Basic EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Diluted EPS (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| Cash EPS (Rs.) | 123.76 | 63.33 | 50.27 | 40.60 | 34.15 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 320.80 | 226.67 | 186.00 | 154.66 | 130.88 |
| Dividend / Share (Rs.) | 24.00 | 16.00 | 12.00 | 9.60 | 7.20 |
| Revenue From Operations / Share (Rs.) | 395.12 | 351.96 | 310.09 | 266.16 | 235.31 |
| PBDIT / Share (Rs.) | 104.20 | 81.85 | 65.00 | 54.03 | 42.84 |
| PBIT / Share (Rs.) | 91.25 | 71.53 | 55.62 | 44.56 | 32.88 |
| PBT / Share (Rs.) | 140.82 | 71.26 | 55.44 | 44.24 | 32.40 |
| Net Profit / Share (Rs.) | 110.80 | 53.01 | 40.90 | 31.13 | 24.19 |
| PBDIT Margin (%) | 26.37 | 23.25 | 20.96 | 20.29 | 18.20 |
| PBIT Margin (%) | 23.09 | 20.32 | 17.93 | 16.74 | 13.97 |
| PBT Margin (%) | 35.63 | 20.24 | 17.87 | 16.62 | 13.76 |
| Net Profit Margin (%) | 28.04 | 15.06 | 13.19 | 11.69 | 10.27 |
| Return on Networth / Equity (%) | 34.53 | 23.38 | 21.98 | 20.12 | 18.48 |
| Return on Capital Employeed (%) | 28.04 | 30.97 | 29.05 | 27.86 | 24.30 |
| Return On Assets (%) | 27.85 | 17.09 | 16.12 | 14.93 | 13.18 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.12 | 1.25 | 1.34 | 1.36 | 1.37 |
| Current Ratio (X) | 3.88 | 2.28 | 2.57 | 2.58 | 2.21 |
| Quick Ratio (X) | 3.11 | 1.50 | 1.64 | 1.55 | 1.47 |
| Inventory Turnover Ratio (X) | 1.14 | 1.23 | 0.96 | 1.25 | 1.63 |
| Dividend Payout Ratio (NP) (%) | 14.44 | 22.64 | 23.47 | 23.13 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 12.92 | 18.95 | 19.10 | 17.73 | 0.00 |
| Earning Retention Ratio (%) | 85.56 | 77.36 | 76.53 | 76.87 | 0.00 |
| Cash Earning Retention Ratio (%) | 87.08 | 81.05 | 80.90 | 82.27 | 0.00 |
| Interest Coverage Ratio (X) | 277.95 | 300.80 | 346.74 | 171.83 | 89.67 |
| Interest Coverage Ratio (Post Tax) (X) | 163.32 | 195.80 | 219.19 | 100.00 | 51.63 |
| Enterprise Value (Cr.) | 3626.89 | 2494.10 | 1093.81 | 855.55 | 600.68 |
| EV / Net Operating Revenue (X) | 5.55 | 4.29 | 2.13 | 1.94 | 1.54 |
| EV / EBITDA (X) | 21.05 | 18.43 | 10.18 | 9.58 | 8.48 |
| MarketCap / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| Retention Ratios (%) | 85.55 | 77.35 | 76.52 | 76.86 | 0.00 |
| Price / BV (X) | 7.10 | 6.75 | 3.74 | 3.62 | 2.96 |
| Price / Net Operating Revenue (X) | 5.76 | 4.35 | 2.24 | 2.10 | 1.65 |
| EarningsYield | 0.04 | 0.03 | 0.05 | 0.05 | 0.06 |
After reviewing the key financial ratios for RPG Life Sciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 8.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 123.76. This value is within the healthy range. It has increased from 63.33 (Mar 24) to 123.76, marking an increase of 60.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 320.80. It has increased from 226.67 (Mar 24) to 320.80, marking an increase of 94.13.
- For Dividend / Share (Rs.), as of Mar 25, the value is 24.00. This value exceeds the healthy maximum of 3. It has increased from 16.00 (Mar 24) to 24.00, marking an increase of 8.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 395.12. It has increased from 351.96 (Mar 24) to 395.12, marking an increase of 43.16.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 104.20. This value is within the healthy range. It has increased from 81.85 (Mar 24) to 104.20, marking an increase of 22.35.
- For PBIT / Share (Rs.), as of Mar 25, the value is 91.25. This value is within the healthy range. It has increased from 71.53 (Mar 24) to 91.25, marking an increase of 19.72.
- For PBT / Share (Rs.), as of Mar 25, the value is 140.82. This value is within the healthy range. It has increased from 71.26 (Mar 24) to 140.82, marking an increase of 69.56.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 110.80. This value is within the healthy range. It has increased from 53.01 (Mar 24) to 110.80, marking an increase of 57.79.
- For PBDIT Margin (%), as of Mar 25, the value is 26.37. This value is within the healthy range. It has increased from 23.25 (Mar 24) to 26.37, marking an increase of 3.12.
- For PBIT Margin (%), as of Mar 25, the value is 23.09. This value exceeds the healthy maximum of 20. It has increased from 20.32 (Mar 24) to 23.09, marking an increase of 2.77.
- For PBT Margin (%), as of Mar 25, the value is 35.63. This value is within the healthy range. It has increased from 20.24 (Mar 24) to 35.63, marking an increase of 15.39.
- For Net Profit Margin (%), as of Mar 25, the value is 28.04. This value exceeds the healthy maximum of 10. It has increased from 15.06 (Mar 24) to 28.04, marking an increase of 12.98.
- For Return on Networth / Equity (%), as of Mar 25, the value is 34.53. This value is within the healthy range. It has increased from 23.38 (Mar 24) to 34.53, marking an increase of 11.15.
- For Return on Capital Employeed (%), as of Mar 25, the value is 28.04. This value is within the healthy range. It has decreased from 30.97 (Mar 24) to 28.04, marking a decrease of 2.93.
- For Return On Assets (%), as of Mar 25, the value is 27.85. This value is within the healthy range. It has increased from 17.09 (Mar 24) to 27.85, marking an increase of 10.76.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.12. It has decreased from 1.25 (Mar 24) to 1.12, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 3.88. This value exceeds the healthy maximum of 3. It has increased from 2.28 (Mar 24) to 3.88, marking an increase of 1.60.
- For Quick Ratio (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 2. It has increased from 1.50 (Mar 24) to 3.11, marking an increase of 1.61.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.23 (Mar 24) to 1.14, marking a decrease of 0.09.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 14.44. This value is below the healthy minimum of 20. It has decreased from 22.64 (Mar 24) to 14.44, marking a decrease of 8.20.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 12.92. This value is below the healthy minimum of 20. It has decreased from 18.95 (Mar 24) to 12.92, marking a decrease of 6.03.
- For Earning Retention Ratio (%), as of Mar 25, the value is 85.56. This value exceeds the healthy maximum of 70. It has increased from 77.36 (Mar 24) to 85.56, marking an increase of 8.20.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 87.08. This value exceeds the healthy maximum of 70. It has increased from 81.05 (Mar 24) to 87.08, marking an increase of 6.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 277.95. This value is within the healthy range. It has decreased from 300.80 (Mar 24) to 277.95, marking a decrease of 22.85.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 163.32. This value is within the healthy range. It has decreased from 195.80 (Mar 24) to 163.32, marking a decrease of 32.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,626.89. It has increased from 2,494.10 (Mar 24) to 3,626.89, marking an increase of 1,132.79.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.55. This value exceeds the healthy maximum of 3. It has increased from 4.29 (Mar 24) to 5.55, marking an increase of 1.26.
- For EV / EBITDA (X), as of Mar 25, the value is 21.05. This value exceeds the healthy maximum of 15. It has increased from 18.43 (Mar 24) to 21.05, marking an increase of 2.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For Retention Ratios (%), as of Mar 25, the value is 85.55. This value exceeds the healthy maximum of 70. It has increased from 77.35 (Mar 24) to 85.55, marking an increase of 8.20.
- For Price / BV (X), as of Mar 25, the value is 7.10. This value exceeds the healthy maximum of 3. It has increased from 6.75 (Mar 24) to 7.10, marking an increase of 0.35.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.76. This value exceeds the healthy maximum of 3. It has increased from 4.35 (Mar 24) to 5.76, marking an increase of 1.41.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in RPG Life Sciences Ltd:
- Net Profit Margin: 28.04%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 28.04% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 34.53% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 163.32
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.11
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33 (Industry average Stock P/E: 53.16)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 28.04%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | RPG House, Mumbai Maharashtra 400030 | investorservices@rpgls.com http://www.rpglifesciences.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Harsh V Goenka | Chairman |
| Mr. Ashok Nair | Managing Director |
| Mr. Rajat Bhargava | Non Executive Director |
| Mr. Yugal Sikri | Non Executive Director |
| Ms. Vasundhara Patni | Non Executive Director |
| Mr. Manoj K Maheshwari | Independent Director |
| Ms. Zahabiya Khorakiwala | Independent Director |
| Mr. Bhaskar Iyer | Independent Director |
| Mr. Sachin Nandgaonkar | Independent Director |
| Ms. Radhika Gupta | Independent Director |
| Mr. Hiten Kotak | Independent Director |
| Mr. Anil Matai | Independent Director |
FAQ
What is the intrinsic value of RPG Life Sciences Ltd?
RPG Life Sciences Ltd's intrinsic value (as of 20 November 2025) is 2275.52 which is 2.27% higher the current market price of 2,225.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 3,675 Cr. market cap, FY2025-2026 high/low of 2,725/1,772, reserves of ₹541 Cr, and liabilities of 706 Cr.
What is the Market Cap of RPG Life Sciences Ltd?
The Market Cap of RPG Life Sciences Ltd is 3,675 Cr..
What is the current Stock Price of RPG Life Sciences Ltd as on 20 November 2025?
The current stock price of RPG Life Sciences Ltd as on 20 November 2025 is 2,225.
What is the High / Low of RPG Life Sciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of RPG Life Sciences Ltd stocks is 2,725/1,772.
What is the Stock P/E of RPG Life Sciences Ltd?
The Stock P/E of RPG Life Sciences Ltd is 33.0.
What is the Book Value of RPG Life Sciences Ltd?
The Book Value of RPG Life Sciences Ltd is 335.
What is the Dividend Yield of RPG Life Sciences Ltd?
The Dividend Yield of RPG Life Sciences Ltd is 0.90 %.
What is the ROCE of RPG Life Sciences Ltd?
The ROCE of RPG Life Sciences Ltd is 32.8 %.
What is the ROE of RPG Life Sciences Ltd?
The ROE of RPG Life Sciences Ltd is 25.5 %.
What is the Face Value of RPG Life Sciences Ltd?
The Face Value of RPG Life Sciences Ltd is 8.00.